Effectiveness of cytoflavin in patients with high risk development of cerebrovascular diseases.
Annotatsiya
The aim of the study was to test the screening of the risk of developing cerebrovascular diseases and assess the e ff ectiveness of cyto fl avin in patients with a high risk of developing this pathology. In addition to general clinical screening (determination of glucose and cholesterol levels in the blood, control of blood pressure and pulse, determination of body mass index), assessment of neurological status using an outpatient scale for assessing chronic cerebral ischemia A.I. Fedina and assessment of the level of cognitive functions — using the Mini-KOG test. Using screening, 64 people were examined, the average age of which was 50.5 ± 11.2 years. Surveyed with a high level of risk of developing pathology for the preventive purpose was prescribed Cytoflavin: 2 tablets. 2 times a day, a course of 30 days, with dynamic monitoring of the condition. Screening for assessing the risk of developing cerebrovascular diseases has shown its e ff ectiveness and allowed us to identify a group of patients at high risk of developing pathology. Patients of this group showed cerebral complaints, signs of asthenoneurotic syndrome and cognitive deficiency. The use of Cytoflavin helped to reduce the manifestations of asthenoneurotic syndrome and improve cognitive functions, had a positive e ff ect on the concentration of attention, memory and thinking. However, the study was pilot in nature and its results can be used in planning further research.